CRSP

#1262
CRISPR Therapeutics AG
56.71 USD
+3.43%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
56.33
56.97
Intervallo Annuale
33.03
78.48
Variazione giornaliera
+3.43%
Variazione Mensile
+14.57%
Variazione di 6 mesi
-19.04%
Variazione Annuale
+47.95%
Chiusura Precedente
54.83
Apertura
56.63
Bid
Ask
Minimo
56.33
High
56.97
Volume
370
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 5.44 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-8.11
Rapporto prezzo/fatturato
1 343.5

CRISPR Therapeutics AG

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

Notizie